56 reports of this reaction
3.3% of all NAFCILLIN SODIUM reports
#2 most reported adverse reaction
RASH is the #2 most commonly reported adverse reaction for NAFCILLIN SODIUM, manufactured by Athenex Pharmaceutical Division, LLC.. There are 56 FDA adverse event reports linking NAFCILLIN SODIUM to RASH. This represents approximately 3.3% of all 1,697 adverse event reports for this drug.
Patients taking NAFCILLIN SODIUM who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH is moderately reported among NAFCILLIN SODIUM users, representing a notable but not dominant share of adverse events.
In addition to rash, the following adverse reactions have been reported for NAFCILLIN SODIUM:
The following drugs have also been linked to rash in FDA adverse event reports:
RASH has been reported as an adverse event in 56 FDA reports for NAFCILLIN SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH accounts for approximately 3.3% of all adverse event reports for NAFCILLIN SODIUM, making it one of the most commonly reported side effect.
If you experience rash while taking NAFCILLIN SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.